182 related articles for article (PubMed ID: 24904098)
1. Is glutamine depletion needed in ALL disease?
Avramis VI
Blood; 2014 Jun; 123(23):3532-3. PubMed ID: 24904098
[No Abstract] [Full Text] [Related]
2. The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.
Chan WK; Lorenzi PL; Anishkin A; Purwaha P; Rogers DM; Sukharev S; Rempe SB; Weinstein JN
Blood; 2014 Jun; 123(23):3596-606. PubMed ID: 24659632
[TBL] [Abstract][Full Text] [Related]
3. A new mechanism of leukemia drug resistance?
Williams DA
N Engl J Med; 2007 Jul; 357(1):77-8. PubMed ID: 17611211
[No Abstract] [Full Text] [Related]
4. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Chan WK; Horvath TD; Tan L; Link T; Harutyunyan KG; Pontikos MA; Anishkin A; Du D; Martin LA; Yin E; Rempe SB; Sukharev S; Konopleva M; Weinstein JN; Lorenzi PL
Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.
Iwamoto S; Mihara K; Downing JR; Pui CH; Campana D
J Clin Invest; 2007 Apr; 117(4):1049-57. PubMed ID: 17380207
[TBL] [Abstract][Full Text] [Related]
6. Circumventing the side effects of L-asparaginase.
Fonseca MHG; Fiúza TDS; Morais SB; Souza TACB; Trevizani R
Biomed Pharmacother; 2021 Jul; 139():111616. PubMed ID: 33932739
[TBL] [Abstract][Full Text] [Related]
7.
Van Trimpont M; Schalk AM; De Visser Y; Nguyen HA; Reunes L; Vandemeulebroecke K; Peeters E; Su Y; Lee H; Lorenzi PL; Chan WK; Mondelaers V; De Moerloose B; Lammens T; Goossens S; Van Vlierberghe P; Lavie A
Haematologica; 2023 Feb; 108(2):409-419. PubMed ID: 35979719
[TBL] [Abstract][Full Text] [Related]
8. Tumoral microenvironment prevents de novo asparagine biosynthesis in B cell lymphoma, regardless of ASNS expression.
Grima-Reyes M; Vandenberghe A; Nemazanyy I; Meola P; Paul R; Reverso-Meinietti J; Martinez-Turtos A; Nottet N; Chan WK; Lorenzi PL; Marchetti S; Ricci JE; Chiche J
Sci Adv; 2022 Jul; 8(27):eabn6491. PubMed ID: 35857457
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.
Ben Tanfous M; Sharif-Askari B; Ceppi F; Laaribi H; Gagné V; Rousseau J; Labuda M; Silverman LB; Sallan SE; Neuberg D; Kutok JL; Sinnett D; Laverdière C; Krajinovic M
Clin Cancer Res; 2015 Jan; 21(2):329-34. PubMed ID: 24907114
[TBL] [Abstract][Full Text] [Related]
10. A Patent Review on the Use of L-Asparaginase in the Treatment of Acute Lymphocytic Leukemia.
Freire DA; Lisboa Magalháes IC; Tramontina Florean EOP; Florindo Guedes MI
Recent Adv Drug Deliv Formul; 2021; 15(1):37-45. PubMed ID: 33685385
[TBL] [Abstract][Full Text] [Related]
11. Asparaginase use for the treatment of acute lymphoblastic leukemia.
Barba P; Dapena JL; Montesinos P; Rives S
Med Clin (Barc); 2017 Mar; 148(5):225-231. PubMed ID: 28118965
[No Abstract] [Full Text] [Related]
12. Management of L-asparaginase induced prothrombotic state in acute lymphoblastic leukemia.
Parma M; Belotti D; Pogliani EM
Haematologica; 1996; 81(2):191. PubMed ID: 8641657
[No Abstract] [Full Text] [Related]
13. Asparagine synthetase polymorphisms and toxicity and efficacy of asparaginases.
Avramis VI
Clin Cancer Res; 2015 Jan; 21(2):230-2. PubMed ID: 25294910
[TBL] [Abstract][Full Text] [Related]
14. In silico engineering of L-asparaginase to have reduced glutaminase side activity for effective treatment of acute lymphoblastic leukemia.
Ln R; Doble M; Rekha VP; Pulicherla KK
J Pediatr Hematol Oncol; 2011 Dec; 33(8):617-21. PubMed ID: 22042278
[TBL] [Abstract][Full Text] [Related]
15. High-dose methotrexate and asparaginase for the treatment of children with acute lymphoblastic leukemia: why and how?
Kamen BA
J Pediatr Hematol Oncol; 2004 Jun; 26(6):333-5. PubMed ID: 15167344
[No Abstract] [Full Text] [Related]
16. Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity.
Dübbers A; Würthwein G; Müller HJ; Schulze-Westhoff P; Winkelhorst M; Kurzknabe E; Lanvers C; Pieters R; Kaspers GJ; Creutzig U; Ritter J; Boos J
Br J Haematol; 2000 May; 109(2):427-9. PubMed ID: 10848836
[TBL] [Abstract][Full Text] [Related]
17. The molecular perspective: l-asparaginase.
Goodsell DS
Stem Cells; 2005 May; 23(5):710-1. PubMed ID: 15849179
[No Abstract] [Full Text] [Related]
18. 50 Years Ago in The Journal of Pediatrics: L-Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: Optimizing Efficacy and Minimizing Toxicity.
Bourgeois W
J Pediatr; 2020 Sep; 224():86. PubMed ID: 32826033
[No Abstract] [Full Text] [Related]
19. Asparaginase in acute lymphoblastic leukemia.
Kawedia JD; Rytting ME
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S14-7. PubMed ID: 25486949
[TBL] [Abstract][Full Text] [Related]
20. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
